

Amendments to the Claims Pursuant to
37 C.F.R. § 1.121 Revised Format

We claim:

1. (currently amended) A formulation comprising olanzapine pamoate monohydrate ~~olanzapine or a pamoate salt or solvate thereof~~ as an active ingredient and one or more carriers selected from the group consisting of an oleaginous carrier or cholesterol microsphere carrier wherein said formulation has a prolonged sustained release of greater than 7 days and a burst release of less than 15% of the active ingredient.

2. (cancelled)

3. A formulation as claimed in Claim 1 wherein said carrier is oleaginous.

4. (currently amended) A formulation of Claim 1 wherein said carrier is selected from the group consisting of ~~PLURONICS~~ nonionic copolymers of propylene oxide and ethylene oxide, cellulosic, gums, polysaccharide gums, vegetable oils, refined fractionated oils, sucrose diacetate hexaisobutyrate, chitosan, lecithin, and ~~POVIDONE~~ polyvinyl pyrrolidone.

5. (currently amended) A formulation as claimed in Claim 4 wherein said carrier is selected from the group consisting of ~~PLURONICS~~ nonionic copolymers of propylene oxide and ethylene oxide, cellulosic gums, polysaccharide gums, vegetable oils, and refined fractionated oils.

6. (original) A formulation as claimed by Claim 2 wherein the formulation further comprises one or more pharmaceutically acceptable excipients.

7. (original) A formulation as claimed by Claim 6 wherein the pharmaceutically acceptable excipient is selected from the group consisting of a gelling agent and an antihydration agent.

8. (cancelled)

9. (cancelled)

10. (original) A formulation as claimed in Claim 1 wherein the carrier is a cholesterol microparticle.

11. (original) A formulation as claimed in Claim 10 wherein the microparticle is a microsphere.

12. (original) A formulation as claimed in Claim 10 wherein the cholesterol is selected from the group consisting of cholesterol, cholesterol palmitate, cholesterol oleate, cholesterol stearate, and cholesterol hemisuccinate.

13. (original) A formulation as claimed in Claim 10 wherein the microspheres have a particle size of from 20 to 500 μ m.

14. (original) A formulation as claimed in Claim 13 wherein the particle size is from 30 to 200 μ m.

15. (original) A formulation as claimed in Claim 14 wherein the particle size is from 40 to 100 μ m.

16. (original) A formulation as claimed in Claim 10 wherein the microspheres are administered in an oleaginous carrier.

17. (currently amended) A formulation as claimed in Claim 16 wherein the oleaginous carrier is selected from the group consisting of ~~PLURONICS~~ nonionic copolymers of propylene oxide and ethylene oxide, cellulosic gums, polysaccharide gums, vegetable oils, and refined fractionated oils.

18-20. (cancelled)

21. (currently amended) A formulation as claimed in claim 1 ~~Claim 20~~ wherein the active ingredient is milled.

22. (original) A formulation as claimed in Claim 21 wherein the particle size is from 20 to 60 μ m.

23. (original) A formulation as claimed in Claim 22 wherein the particle size is from 5 to 20 μ m.

24. (original) A formulation as claimed in Claim 23 wherein the milled particles are less than or equal to 5µm.

25-33. (cancelled)

34. (new) A formulation comprising olanzapine pamoate monohydrate as an active ingredient, and one or more carriers.